Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan

被引：18

作者：

Ikeda, Fumiaki ^{[1
]}

Saika, Takeshi ^{[1
]}

Sato, Yumie ^{[1
]}

Suzuki, Makoto ^{[1
]}

Hasegawa, Miyuki ^{[1
]}

Mikawa, Takashi ^{[1
]}

Kobayashi, Intetsu ^{[2
]}

Tsuji, Akiyoshi ^{[2
]}

机构：

[1] Mitsubishi Chem Corp, Div Chemotherapy, Itabashi Ku, Tokyo 1748555, Japan

[2] Toho Univ, Dept Infect Control & Prevent, Sch Nursing, Fac Med, Tokyo, Japan

来源：

MEDICAL MYCOLOGY | 2009年 / 47卷 / 02期

关键词：

antifungal agent; in vitro susceptibility; pediatric patient; Candida; Aspergillus; IN-VITRO ACTIVITY; GLOBAL SURVEILLANCE; SUSCEPTIBILITY; CASPOFUNGIN; FK463;

D O I：

10.1080/13693780802262123

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The in vitro antifungal activities of micafungin in comparison to caspofungin, fluconazole, itraconazole, voriconazole, and amphotericin B were evaluated against 93 Candida and 23 Aspergillus isolates recovered from pediatric patients with fungal infections. MICs were determined by the CLSI M27-A2 and M38-A for Candida and Aspergillus species, respectively. Micafungin showed potent activity against Candida albicans, Candida tropicalis, and Candida glabrata with a MIC range of = 0.002 to 0.015g/ml. In contrast, micafungin demonstrated higher MIC levels against Candida parapsilosis with a MIC range of 0.12 to 2 g/ml. Micafungin showed potent antifungal activity against Aspergillus species tested with a MIC range of 0.004 to 0.015 g/ml. Overall, micafungin had excellent in vitro antifungal activities against Candida and Aspergillus species recovered from pediatric patients with fungal infections.

引用

页码：145 / 148

页数：4

共 13 条

[1]

[Anonymous], 2002, CLSI (NCCLS) M27-A2

[2] Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp. [J].

Arikan, S ;

Yurdakul, P ;

Hascelik, G .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) :2640-2643

[3] Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus [J].

Bartizal, C ;

Odds, FC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) :2100-2107

[4] A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients [J].

de Wet, N ;

Llanos-Cuentas, A ;

Suleiman, J ;

Baraldi, E ;

Krantz, EF ;

Della Negra, M ;

Diekmann-Berndt, H .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (06) :842-849

[5] Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus [J].

Hatano, K ;

Morishita, Y ;

Nakai, T ;

Ikeda, F .

JOURNAL OF ANTIBIOTICS, 2002, 55 (02) :219-222

[6] Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing [J].

Hope, William W. ;

Seibel, Nita L. ;

Schwartz, Cindy L. ;

Arrieta, Antonio ;

Flynn, Patricia ;

Shad, Aziza ;

Albano, Edythe ;

Keirns, James J. ;

Buell, Donald N. ;

Gumbo, Tawanda ;

Drusano, George L. ;

Walsh, Thomas J. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (10) :3714-3719

[7] A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan [J].

Kohno, S ;

Masaoka, T ;

Yamaguchi, H ;

Mori, T ;

Urabe, A ;

Ito, A ;

Niki, Y ;

Ikemoto, H .

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2004, 36 (05) :372-379

[8] Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species [J].

Odds, FC ;

Motyl, M ;

Andrade, R ;

Bille, J ;

Cantón, E ;

Cuenca-Estrella, M ;

Davidson, A ;

Durussel, C ;

Ellis, D ;

Foraker, E ;

Fothergill, AW ;

Ghannoum, MA ;

Giacobbe, RA ;

Gobernado, M ;

Handke, R ;

Laverdière, M ;

Lee-Yang, W ;

Merz, WG ;

Ostrosky-Zeichner, L ;

Pemán, J ;

Perea, S ;

Perfect, JR ;

Pfaller, MA ;

Proia, L ;

Rex, JH ;

Rinaldi, MG ;

Rodriguez-Tudela, JL ;

Schell, WA ;

Shields, C ;

Sutton, DA ;

Verweij, PE ;

Warnock, DW .

JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (08) :3475-3482

[9] Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States [J].

Ostrosky-Zeichner, L ;

Rex, JH ;

Pappas, PG ;

Hamill, RJ ;

Larsen, RA ;

Horowitz, HW ;

Powderly, WG ;

Hyslop, N ;

Kauffman, CA ;

Cleary, J ;

Mangino, JE ;

Lee, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) :3149-3154

[10] In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin:: Six years of global surveillance [J].

Pfaller, M. A. ;

Boyken, L. ;

Hollis, R. J. ;

Kroeger, J. ;

Messer, S. A. ;

Tendolkar, S. ;

Diekema, D. J. .

JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (01) :150-156

← 1 2 →